Telesta Therapeutics Inc. (A subsidiary of Prometic Life Sciences Inc.)

Belkins
Telesta Therapeutics was a biotechnology company focused on the licensing/acquisition .

Related News

AMYRIS COLLABORATES WITH INFECTIOUS DISEASE RESEARCH INSTITUTE TO ADVANCE A NOVEL RIBONUCLEIC ACID VACCINE PLATFORM WITH COVID-19 VACCINE

Amyris | October 23, 2020

news image

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI's RNA vacci...

Read More

GSK COLLABORATES WITH VIR BIOTECHNOLOGY TO FIND CORONAVIRUS SOLUTIONS

HospiMedica International | April 07, 2020

news image

GlaxoSmithKline plc (London, UK) and Vir Biotechnology, Inc. (San Francisco, CA, USA) have entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbr...

Read More

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne | August 04, 2020

news image

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More

CELL AND GENE THERAPY

BIOCYTOGEN COMPLETES A NEW ROUND OF FINANCING TOTALING TENS OF MILLIONS OF DOLLARS

Biocytogen | June 23, 2021

news image

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...

Read More

Amyris | October 23, 2020

news image

AMYRIS COLLABORATES WITH INFECTIOUS DISEASE RESEARCH INSTITUTE TO ADVANCE A NOVEL RIBONUCLEIC ACID VACCINE PLATFORM WITH COVID-19 VACCINE

Amyris, Inc. (Nasdaq: AMRS), a leading synthetic biotechnology company in Clean Health and Beauty markets through its consumer brands, and a top supplier of sustainable and natural ingredients, today announced the signing of a Collaboration Agreement and License Agreement with the Infectious Disease Research Institute (IDRI) to advance a novel ribonucleic acid (RNA) vaccine platform, including accelerating the development of a COVID-19 vaccine. The collaboration will combine IDRI's RNA vacci...

Read More

HospiMedica International | April 07, 2020

news image

GSK COLLABORATES WITH VIR BIOTECHNOLOGY TO FIND CORONAVIRUS SOLUTIONS

GlaxoSmithKline plc (London, UK) and Vir Biotechnology, Inc. (San Francisco, CA, USA) have entered into a collaboration to research and develop solutions for coronaviruses, including SARS-CoV-2, the virus that causes COVID-19. The collaboration will use Vir’s proprietary monoclonal antibody platform technology to accelerate existing and identify new anti-viral antibodies that could be used as therapeutic or preventative options to help address the current COVID-19 pandemic and future outbr...

Read More

Bio-Techne | August 04, 2020

news image

BIO-TECHNE AND KANTARO BIOSCIENCES ANNOUNCED THE LAUNCH OF THE COVID-SEROINDEX, A KANTARO QUANTITATIVE SARS-COV-2 IGG ANTIBODY RUO KIT

Bio-Techne Corporation (NASDAQ:TECH) and the Mount Sinai Health System in New York, through its commercial affiliate Kantaro Biosciences LLC (Kantaro), today announced the anticipated launch of the COVID-SeroIndex, a Kantaro Quantitative SARS-CoV-2 IgG Antibody RUO kit. Bio-Techne and Kantaro will leverage a joint commercialization and distribution team to support rapid distribution of the assay to the vaccine development community. The COVID-SeroIndex test kit is expected to be available ...

Read More

CELL AND GENE THERAPY

Biocytogen | June 23, 2021

news image

BIOCYTOGEN COMPLETES A NEW ROUND OF FINANCING TOTALING TENS OF MILLIONS OF DOLLARS

Biocytogen, a worldwide biotechnology organization zeroed in on neutralizer drug innovative work (R&D) utilizing creative genetically designed creature models, today declared the fruitful culmination of another round of financing adding up to a huge number of dollars. The financing was together finished by Lake Bleu Capital, CPE, Octagon Capital and OrbiMed. Biocytogen Pharmaceuticals (Beijing) Co., Ltd. was set up in 2009. Utilizing its primary quality altering innovation, th...

Read More